azd1775
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2017 (NCT03333824)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase WEE1INHIBITOR
WEE1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03718143 | Phase 2 | Apr 1, 2019 | New York University |
| NCT03668340 | Phase 2 | Oct 31, 2018 | AstraZeneca, Harvard University |
| NCT03333824 | Phase 1 | Dec 1, 2017 | AstraZeneca, Henry Ford Health System, IQVIA |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 1 | 2 | 2017 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Henry Ford Health System | Academic/Hospital | 1 | 0 | 1 | 2017 |
| IQVIA | For profit | 1 | 0 | 1 | 2017 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2019 |
5 organizations
Page 1 / 1